FOLH1 and neoplasm: We have shown that 131I-MIP-1095 displays rapid and high uptake and prolonged retention in tumor lesions and that 124I-MIP-1095 can be used to confirm PSMA-avidity and estimate normal organ dosimetry prior to treatment.